LAG3 (CD223) as a cancer immunotherapy target.

@article{Andrews2017LAG3A,
  title={LAG3 (CD223) as a cancer immunotherapy target.},
  author={Lawrence P. Andrews and Ariel E. Marciscano and Charles G. Drake and Dario A A Vignali},
  journal={Immunological reviews},
  year={2017},
  volume={276 1},
  pages={
          80-96
        }
}
Despite the impressive impact of CTLA4 and PD1-PDL1-targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond. Consequently, the focus has shifted to targeting alternative inhibitory receptors (IRs) and suppressive mechanisms within the tumor microenvironment. Lymphocyte activation gene-3 (LAG3) (CD223) is the third IR to be targeted in the clinic, consequently garnering considerable interest and scrutiny. LAG3 upregulation is required to control overt… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 77 CITATIONS, ESTIMATED 69% COVERAGE

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

  • Molecular Cancer
  • 2019
VIEW 12 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy

  • Genes & cancer
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Check point inhibitors as therapies for infectious diseases.

  • Current opinion in immunology
  • 2017
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2017
2019

CITATION STATISTICS

  • 7 Highly Influenced Citations

  • Averaged 26 Citations per year from 2017 through 2019

  • 109% Increase in citations per year in 2019 over 2018

References

Publications referenced by this paper.
SHOWING 1-10 OF 96 REFERENCES

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 1997
VIEW 23 EXCERPTS
HIGHLY INFLUENTIAL